Antilipolytic drugs for the prevention of primary ventricular fibrillation.
Oliver
M F
MF
Department of Cardiology, University of Edinburgh, Edinburgh, UK.
D002395:Catecholamines / Q000037:antagonists & inhibitors / Q000097:blood; D005230:Fatty Acids, Nonesterified / Q000097:blood; D005947:Glucose / Q000008:administration & dosage; D006801:Humans; D007328:Insulin / Q000008:administration & dosage; D008066:Lipolysis / Q000187:drug effects*; D017202:Myocardial Ischemia / Q000378:metabolism; D011188:Potassium / Q000008:administration & dosage; D014693:Ventricular Fibrillation / Q000517:prevention & control*
D002395:Catecholamines; D005230:Fatty Acids, Nonesterified; D007328:Insulin; D005947:Glucose; D011188:Potassium